NCT02082691No Longer Available不适用
Single Patient IND: Continued Administration of G-202 to a Patient With Advanced Hepatocellular Carcinoma Previously Treated With G-202 and Receiving Clinical Benefit
Devalingam Mahalingam0 个研究点开始时间: 2014年3月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of hepatocellular carcinoma
- •Participation in prior research study where G-202 was administered
- •Tolerance of G-202 treatment
- •Demonstration of stable disease
排除标准
- •Disease progression
- •Occurrence of unacceptable toxicity
研究者
Devalingam Mahalingam
Prinicipal Investigator
The University of Texas Health Science Center at San Antonio
相似试验
终止
1 期
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting BeadsNeoplasm MetastasesMelanomaColorectal NeoplasmsNCT01336985National Institutes of Health Clinical Center (CC)5
招募中
不适用
Prospective collection of data of patients with liver cancers being treated with proton therapyCTRI/2020/12/030087Apollo Proton Cancer Centre
已完成
2 期
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001Hepatocellular CarcinomaNCT00775073Gerhard Treiber33
Unknown
2 期
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLMColorectal Cancer Liver MetastasesNCT05485909Sun Yat-sen University32
Unknown
不适用
Intermediate-size IND for Treatment of KRAS G12V-mutant TumorsKRAS G12V Mutant Advanced Epithelial CancersNCT05389514Providence Health & Services